Provided are methods of Diagnosing and Treating Disorders associated with excess amounts of eosinophils or activity, including but not limited to Asthma. Also provided are methods of selecting or identifying patients for Treatment with certain therapeutic agents which are inhibitors of Th2.Claim 1: a method for Predicting the response of a patient with Asthma or a Respiratory disorder to a Therapy that includes a Th2 Pathway Inhibitor, the method comprises: obtaining a Biological sample from the patient, measure the mRNA level of at least one, at least D. Or at least three markers in the sample selected CSF1, Meis2, lgals12, ido1, thbs4, Olig2,Alox15, siglec8, CCL23, pyroxd2, HSD3B7, Sord, ASB2, cacng6, gpr44, mgat3, slc47a1, smpd3, CCR3, CLC, CYP4F12 abtb2, and compare the level of mRNA detected in the sample with a reference levelAnd predict that the patient will respond to Therapy when the mRNA level measured in the sample is high compared to the reference level and predict the patient did not respond to Therapy when the mRNA level measured in the sample is small compared with the reference level.Se proporcionan los métodos de diagnosticar y tratar trastornos relacionados con el exceso de cantidades o actividad de eosinófilos, que incluye pero sin limitación asma. También se proporcionan los métodos de seleccionar o identificar pacientes para el tratamiento con ciertos agentes terapéuticos que son inhibidores de TH2. Reivindicación 1: Un método para predecir la respuesta de un paciente que padece de asma o de un trastorno respiratorio a una terapia que comprende un inhibidor de la vía de TH2, el método comprende: obtener una muestra biológica del paciente, medir el nivel de mARN de al menos uno, al menos dos o al menos tres marcadores en la muestra seleccionados de CSF1, MEIS2, LGALS12, IDO1, THBS4, OLIG2, ALOX15, SIGLEC8, CCL23, PYROXD2, HSD3B7, SORD, ASB2, CACNG6, GPR44, MGAT3, SLC47A1, SMPD3, CCR3, CLC, CYP4F12, y ABTB2, comparar el nivel de mARN detectado en
